Drug class in one race
Dopamine D3/D2 receptor (partial agonist) drugs for Schizophrenia
5 tracked Dopamine D3/D2 receptor (partial agonist) drugs in the Schizophrenia race. The class explanation lives on the Dopamine D3/D2 receptor (partial agonist) page; the full indication pipeline across every mechanism is on the Schizophrenia page.
1 approved / phase 42 Phase 32 Phase 1/2
Head-to-head evidence: Cariprazine (Chengdu Kanghong) vs Cariprazine (Vraylar) · Cariprazine (Chengdu Kanghong) vs JX11502MA · Cariprazine long-acting injection (Mapi Pharma) vs Cariprazine (Vraylar) · Cariprazine (Vraylar) vs JX11502MA · Cariprazine (Vraylar) vs QLM1016 · Cariprazine long-acting injection (Mapi Pharma) vs JX11502MA